Verlukast

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326811

CAS#: 120443-16-5

Description: Verlukast, also known as MK-0679, is a (R)-enantiomer of MK-571 and a potent and selective LTD4 receptor antagonist. Verlukast showed [3H]leukotriene D4 binding in guinea-pig (IC50 = 3.1 +/- 0.5 nM) and human (IC50 = 8.0 +/- 3.0 nM) lung homogenates and dimethyl sulfoxide differentiated U937 cell membrane preparations (IC50 = 10.7 +/- 1.6 nM) but is essentially inactive versus [3H]leukotriene C4 binding in guinea-pig lung homogenates (IC50 values of 19 and 33 microM). Verlukast was in clinical development for the treatment of asthma and related diseases. (last updated: 8/8/2016)

Chemical Structure

img
Verlukast
CAS# 120443-16-5
Instruction

Theoretical Analysis

MedKoo Cat#: 326811
Name: Verlukast
CAS#: 120443-16-5
Chemical Formula: C26H27ClN2O3S2
Exact Mass: 514.12
Molecular Weight: 515.083
Elemental Analysis: C, 60.63; H, 5.28; Cl, 6.88; N, 5.44; O, 9.32; S, 12.45

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: L 668,019; L 668019; L-668,019; MK 0679; MK 679; MK-679; R-(-)-MK 571; Verlukast.

IUPAC/Chemical Name: (R,E)-3-(((3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoic acid

InChi Key: AXUZQJFHDNNPFG-LHAVAQOQSA-N

InChi Code: InChI=1S/C26H27ClN2O3S2/c1-29(2)24(30)12-14-33-26(34-15-13-25(31)32)20-5-3-4-18(16-20)6-10-22-11-8-19-7-9-21(27)17-23(19)28-22/h3-11,16-17,26H,12-15H2,1-2H3,(H,31,32)/b10-6+/t26-/m1/s1

SMILES Code: O=C(O)CCS[C@H](C1=CC=CC(/C=C/C2=NC3=CC(Cl)=CC=C3C=C2)=C1)SCCC(N(C)C)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 515.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Nicoll-Griffith DA, Gupta N, Twa SP, Williams H, Trimble LA, Yergey JA. Verlukast (MK-0679) conjugation with glutathione by rat liver and kidney cytosols and excretion in the bile. Drug Metab Dispos. 1995 Oct;23(10):1085-93. PubMed PMID: 8654196.

2: Hsieh JY, Lin C, Matuszewski BK. Robotic sample preparation and high-performance liquid chromatographic analysis of verlukast in human plasma. J Chromatogr B Biomed Appl. 1994 Nov 18;661(2):307-12. PubMed PMID: 7894671.

3: Schwartz JI, Margolskee DJ, Bjornsson TD, Williams VC, Hsieh JY, Lin CC, Rogers JD. Oral pharmacokinetics and food interaction of the leukotriene D4 receptor antagonist verlukast. Br J Clin Pharmacol. 1993 Nov;36(5):464-6. PubMed PMID: 12959296; PubMed Central PMCID: PMC1364621.

4: Grossman SJ, Herold EG, Drey JM, Alberts DW, Umbenhauer DR, Patrick DH, Nicoll-Griffith D, Chauret N, Yergey JA. CYP1A1 specificity of Verlukast epoxidation in mice, rats, rhesus monkeys, and humans. Drug Metab Dispos. 1993 Nov-Dec;21(6):1029-36. PubMed PMID: 7905381.

5: Nicoll-Griffith DA, Chauret N, Yergey JA, Trimble LA, Favreau L, Zamboni R, Grossman SJ, Drey J, Herold E. Characterization of verlukast metabolites arising from an epoxide intermediate produced with hepatic microsomes from beta-naphthoflavone-treated rodents (P-4501A1). Drug Metab Dispos. 1993 Sep-Oct;21(5):861-7. PubMed PMID: 7902249.

6: Lammers JW, Van Daele P, Van den Elshout FM, Decramer M, Buntinx A, De Lepeleire I, Friedman B. Bronchodilator properties of an inhaled leukotriene D4 antagonist (verlukast--MK-0679) in asthmatic patients. Pulm Pharmacol. 1992 Jun;5(2):121-5. PubMed PMID: 1611229.

7: Nicoll-Griffith D, Yergey J, Trimble L, Williams H, Rasori R, Zamboni R. In vitro and in vivo biotransformations of the potent leukotriene D4 antagonist verlukast in the rat. Drug Metab Dispos. 1992 May-Jun;20(3):383-9. PubMed PMID: 1355712.

8: Jones TR, Zamboni R, Belley M, Champion E, Charette L, Ford-Hutchinson AW, Gauthier JY, Leger S, Lord A, Masson P, et al. Pharmacology of the leukotriene antagonist verlukast: the (R)-enantiomer of MK-571. Can J Physiol Pharmacol. 1991 Dec;69(12):1847-54. PubMed PMID: 1666333.